PA
CRVS icon

Profund Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Profund Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613K Sell
41,044
-9,191
-18% -$128K 0.02% 489
2026
Q1 		$735K Buy
50,235
+13,172
+36% +$210K 0.03% 433
2025
Q4 		$285K Buy
+37,063
New +$292K 0.01% 911

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Profund Advisors's CRVS Position: Q2 2026 in Review

Profund Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 18% in Q2 2026, selling an estimated $128K and leaving 41,044 shares worth $613K. The position accounts for 0.02% of the portfolio, ranked #489.

Profund Advisors first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. The position peaked at $735K in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Profund Advisors held 41,044 shares of Corvus Pharmaceuticals worth $613K as of Q2 2026.
  • Profund Advisors sold 9,191 Corvus Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Corvus Pharmaceuticals made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #489 holding.
  • Profund Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Profund Advisors's Corvus Pharmaceuticals position peaked at $735K in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.